All In Biotech

Drug Trial Radar · NCT05287113

Study of Retinfanlimab in Combination With INCAGN02385 and INCAGN02390 as First-Line Treatment in Participants With PD-L1-Positive (CPS ≥ 1) Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck

A Randomized, Double-Blind, Multicenter, Phase 2 Study of Retifanlimab in Combination With INCAGN02385 (Anti-LAG-3) and INCAGN02390 (Anti-TIM-3) as First-Line Treatment in Participants With PD-L1-Positive (CPS ≥ 1) Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck

Last checked: Nov 20, 2026Latest source record: Sep 25, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 176 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

176

Actual

Start

Nov 14, 2022

Primary completion

Mar 14, 2025

Study completion Jun 23, 2026

Sponsor

Sponsor type
Industry
First posted
Mar 18, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 99 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the safety and efficacy of the combination of retifanlimab plus INCAGN02385 and retifanlimab plus INCAGN02385 and INCAGN02390 compared with retifanlimab alone as first-line treatment in PD-L1-positive and systemic therapy-naive recurrent/metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN).

Conditions

  • Head and Neck Cancer

Interventions

  • RetifanlimabDrug

    Retifanlimab 500mg will be administered intravenously every 4 weeks.

  • INCAGN02385Drug

    INCAGN02385 350mg will be administered intravenously every 2 weeks.

  • INCAGN02390Drug

    INCAGN02390 400 mg will be administered intravenously every 2 weeks.

  • PlaceboDrug

    Placebo will be administered intravenously.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progeression-free Survival (PFS)Time frame: up to 738 days

Locations

91 sites in 14 countries. Site status is shown where the registry gives one.

  • Mayo Clinic Rochester

    Scottsdale, Arizona

  • City of Hope National Medical Center

    Duarte, California

  • City of Hope Orange County

    Irvine, California

  • University of California San Diego Medical Center, Moores Cancer Center

    La Jolla, California

  • City of Hope-Antelope Valley

    Lancaster, California

  • Innovative Clinical Research Institute

    Long Beach, California

  • City of Hope National Medical Center

    Long Beach, California

  • University of California San Francisco Comprehensive Cancer Center

    San Francisco, California

  • Georgetown University

    Washington D.C., District of Columbia

  • Mayo Clinic Jacksonville

    Jacksonville, Florida

  • Blessed Health Care

    Miami, Florida

  • Moffitt Cancer Center

    Tampa, Florida

  • University of Illinois At Chicago

    Chicago, Illinois

  • University of Iowa

    Iowa City, Iowa

  • University of Kansas Hospital Authority

    Kansas City, Kansas

  • University of Maryland-Greenebaum Cancer Center

    Baltimore, Maryland

  • Dana Farber Cancer Institute

    Boston, Massachusetts

  • University of Michigan Cancer Center

    Ann Arbor, Michigan

  • Barbara Ann Karmanos Cancer Hospital

    Detroit, Michigan

  • Hackensack University Medical Center

    Hackensack, New Jersey

  • Fox Chase Cancer Center

    Philadelphia, Pennsylvania

  • Huntsman Cancer Institute At University of Utah

    Salt Lake City, Utah

  • University of Virginia - Emily Couric Clinical Cancer Center

    Charlottesville, Virginia

  • Kadlec Clinic Hematology and Oncology

    Kennewick, Washington

  • Grand Hospital de Charleroi

    Charleroi, Belgium

  • Jessa Ziekenhuis

    Hasselt, Belgium

  • Gza Sint Augustinus

    Wilrijk, Belgium

  • McGill University Health Centre/Glen Site/Cedars Cancer Centre

    Montreal, Quebec, Canada

  • Chum Hospital Notre Dame

    Montreal, Quebec, Canada

  • McGill University Jewish General Hospital

    Montreal, Quebec, Canada

  • Centre Hospitalier Universitaire de Bordeaux

    Bordeaux, France

  • Institut Curie

    Paris, France

  • Centre Eugene Marquis

    Rennes, France

  • Centre de Lutte Contre Le Cancer - Institut de Cancerologie de L'Ouest - Rene Gauducheau

    Saint-Herblain, France

  • Icans - Institut de Cancerologie Strasbourg Europe

    Strasbourg, France

  • Jsc Evex Hospitals

    K'ut'aisi, Georgia

  • New Hospitals

    Tbilisi, Georgia

  • Jsc Evex Corporation-Caraps Medline

    Tbilisi, Georgia

  • Ltd Cancer Research Centre

    Tbilisi, Georgia

  • University of Cologne

    Cologne, Germany

Showing 40 of 91 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.